Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN), Celldex (CLDX) and Nurix Therapeut...

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Celldex (CLDX) and Nurix Therapeutics (NRIX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Valneva (VALN), Regeneron (REGN) and Telix Pharmaceu...

Analysts Are Bullish on These Healthcare Stocks: Valneva (VALN), Regeneron (REGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals has finished a mid stage study tes...

Regeneron’s POTS Study Wraps Up: What REGN7544 Could Mean for REGN Investors

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The study, officially titled “PRospEctiVe c...

Real-World Asthma Data on Dupixent: What Regeneron and Sanofi Investors Should Know

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alumis Inc. (ALMS), Glaukos (GKOS) and Regeneron (...

Analysts Conflicted on These Healthcare Names: Alumis Inc. (ALMS), Glaukos (GKOS) and Regeneron (REGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Targets Fatty Liver Disease With New Phase 2a Stud...

Regeneron Expands Metabolic Footprint With New Phase 2a Fatty Liver Study

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals, Inc. (REGN) is running a first-in...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REGN	$656.01	+0.63%	708.35K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REGN	$656.01	+0.6%	708.35K
3
4
5
6

REGN

REGN

Get Regeneron Pharmaceuticals Inc. Data in Excel

Get Regeneron Pharmaceuticals Inc. Data in Excel